A high-level memorandum of understanding (MoU) for medical research and development has been signed between the South African Medical Research Council (SAMRC), the department of science and technology (DST) and Swiss drug firm, Novartis.
The MoU, a public private partnership (PPP), aims to establish a framework for potential cooperation between the parties. This will allow for joint research programmes in selected communicable and non-communicable diseases (NCD), improve South African patients’ access to innovative medicines and build up the research & development capabilities and ecosystem in South Africa and Africa.
“Public private partnerships, such as what we are about to embark on, are catalysts that enhance our scientific research and innovation capabilities. These partnerships are visionary and aim to change lives in the present and future,” said Professor Richard Gordon, SAMRC’s executive director: grants, innovation and product development (GIPD